Sponsored by

PuffItUp Dynavap VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Did you know we have lots of smilies for you to use?
  • Need help navigating the forum? Find out how to use our features here.

Research Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain

Baron23

Well-Known Member
Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain
Abstract
We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling either medium dose (3.53%), low dose (1.29%), or placebo cannabis with the primary outcome being VAS pain intensity. Psychoactive side-effects, and neuropsychological performance were also evaluated. Mixed effects regression models demonstrated an analgesic response to vaporized cannabis. There was no significant difference between the two active dose groups’ results (p>0.7). The number needed to treat (NNT) to achieve 30% pain reduction was 3.2 for placebo vs. low dose, 2.9 for placebo vs. medium dose, and 25 for medium vs. low dose. As these NNT are comparable to those of traditional neuropathic pain medications, cannabis has analgesic efficacy with the low dose being, for all intents and purposes, as effective a pain reliever as the medium dose. Psychoactive effects were minimal and well-tolerated, and neuropsychological effects were of limited duration and readily reversible within 1–2 hours. Vaporized cannabis, even at low doses, may present an effective option for patients with treatment-resistant neuropathic pain.


This is a bit of an older article and was posted by @Vicki on another forum where it was brought to the top by a post.

I thought this would be of interest and worth resurrecting
. This is a research report from the National Institutes of Health and completely undermines Rosenberg's BS schedule 1 of MJ. Rosenberg is a complete and utter tool.
 

herbivore21

Well-Known Member
Great stuff! What fascinates me about this study is that it plays up the 'low dose' part when the study says that the medium dose cohort also experienced the same benefits with both groups tolerating any side effects well. Many alternative medications are not so well tolerated and this is a key criterion when comparing MMJ with pharma in a medical setting.
 

Baron23

Well-Known Member
Many alternative medications are not so well tolerated and this is a key criterion when comparing MMJ with pharma in a medical setting.
INdeed! LOL
 

Sponsored by

PuffItUp Dynavap VGoodiez 420EDC
Top